S-1/A: Kindly MD, Inc. Files Amendment No. 7 to Form S-1, Eyes Nasdaq Listing

Kindly MD, Inc. updates its S-1 registration statement, including audited financials for 2023, as it seeks an initial public offering and Nasdaq listing.

Summary

• Kindly MD, Inc., a Utah-based healthcare data company focused on holistic pain management, filed Amendment No. 7 to its Form S-1 registration statement.
• The filing includes audited financial statements for the year ended December 31, 2023.
• The company is pursuing an initial public offering (IPO) of 1,272,727 units, each consisting of one share of common stock, one tradeable warrant, and one non-tradeable warrant, with a proposed offering price of $5.50 per unit.
• Kindly MD has applied to list its Common Stock and Tradeable Warrants on the Nasdaq Capital Market under the symbols KDLY and KDLYW, respectively.
• The company is also registering 1,712,057 shares of common stock for resale by certain selling stockholders.
• The company plans to use the net proceeds from the IPO for general corporate purposes, including capital expenditures, labor, real estate, marketing and sales, and technology development.
• The company had revenues of $3,768,598 for the year ended December 31, 2023, and a net loss of $1,617,461.
• The company is subject to various risks, including those related to the medical marijuana industry, regulatory changes, competition, and the need for additional capital.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has some competitive advantages, it also faces financial challenges and regulatory risks.

Positives

• The company is one of the largest providers of medical evaluation and management services related to treatment recommendations within the medical cannabis program in Utah.
• The company has a unique healthcare model, blending prescribers and licensed behavioral health clinicians into every patient care plan.
• The company has achieved year over year revenue growth to-date, including during the COVID-19 Pandemic.
• The company has contracted with Select Health, Medicare, and Utah Medicaid.
• The company has a highly skilled leadership team in healthcare technology, customer service, patient care, and high-touch interactions.

Negatives

• The company reported a net loss of $1,617,461 for the year ended December 31, 2023.
• The company has a total working capital deficit of $214,906 as of December 31, 2023.
• The company may need additional capital that will dilute the ownership interest of investors.
• The company is controlled by its existing majority shareholder.
• The company is subject to general economic risks.

Risks

• The company's business may suffer if it is unable to attract or retain talented personnel.
• The lack of available and cost-effective directors and officers insurance coverage in the cannabis industry may cause the company to be unable to attract and retain qualified executives.
• Laws and regulations affecting the medical marijuana industry are constantly changing, which could detrimentally affect the company's operation.
• The company's use, disclosure, and other processing of personal information, including health information, is subject to the Health Insurance Portability and Accountability Act (HIPAA), and other federal, state, and foreign data privacy and security laws and regulations.
• The company operates in highly competitive markets and faces competition from large, well-established healthcare providers, traditional retailers, pharmaceutical providers, and technology companies with significant resources.
• The company's operations, although compliant with Utah state law, are still subject to U.S. federal law which classifies cannabis as a Schedule I controlled substance.

Future Outlook

The company expects to continue investing in its growth initiatives, including expanding its client base, enhancing its service offerings, and continuing to improve its operational efficiency.

Industry Context

The company operates in the healthcare and medical cannabis industries, which are subject to evolving regulations and increasing competition. The company's focus on holistic pain management and data collection positions it to address the opioid epidemic and provide evidence-based treatment options.

Comparison to Industry Standards

• The document states that KindlyMD is one of the largest providers of medical evaluation and management services related to treatment recommendations within the medical cannabis program in Utah.
• The document states that KindlyMD is one of a limited number of specialty providers who allow patients to utilize non-opioid alternative medications, such as medical cannabis, concomitantly with opioids with medical supervision by a licensed integration team.
• The document states that the company knows of no other large clinic in Utah or the US which uses this integration model combined with a willingness to incorporate non-traditional medicine.
• The document does not provide specific comparisons to industry standards or comparable companies.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares.
• Employees may benefit from the company's growth and expansion.
• Customers may benefit from the company's focus on holistic pain management and alternative treatment options.

Next Steps

• The company will continue to leverage its growth potential as a leader in specialized data collection and healthcare in the opioid and alternative medicine space.
• The company intends to research and negotiate acquisitions as much as it is able.
• The company will seek out specialty clinics focused on opioid or non-opioid evaluation and management of pain and other chronic illnesses.

Key Dates

Keywords

medical cannabis, initial public offering, healthcare data, pain management, Nasdaq, S-1, opioid epidemic, telehealth, warrants, IPO